F. Genre1, J. Rueda-Gotor2, S. Remuzgo-Martínez3, A. Corrales4, B. Ubilla5, V. Mijares6, C. Fernández-Díaz7, V. Portilla8, R. Blanco9, J. Hernández10, J. Llorca11, R. López-Mejías12, M. González-Gay13
2018 Vol.36, N°2 - PI 0302, PF 0309
Free to view (click on article PDF icon to read the article)
Due to the high incidence of cardiovascular disease in axial spondyloarthritis (axSpA), the search of potential biomarkers that may help to identify patients with high cardiovascular risk is of main importance. Therefore, in this study we assessed the implication of osteoprotegerin (OPG) and sclerostin (SCL), two biomarkers associated with cardiovascular disease and bone metabolism, in the clinical spectrum and atherosclerotic disease of patients with axSpA.
OPG and SCL serum levels were determined in 163 axSpA Spanish patients (119 ankylosing spondylitis and 44 non-radiographic axSpA) and 63 healthy controls by enzyme-linked immunosorbent assay. Carotid ultrasound was performed in axSpA patients to determine the presence of subclinical atherosclerosis (by the identification of abnormally increased carotid intima-media thickness [cIMT] and presence of plaques).
Patients displayed higher OPG but lower SCL levels than controls (p=0.02 and 0.001, respectively). Association of these molecules with some metabolic syndrome features was seen. In this regard, OPG negatively correlated with body mass index (p=0.04) whereas SCL levels were higher in hypertensive patients (p=0.01) and in men (p=0.002). However, serum OPG and SCL were not significantly correlated with cIMT values or presence of plaques when data were adjusted by age at the time of the study, sex, classic cardiovascular risk factors and anti-TNF therapy.
Our results suggest an association of OPG and SCL in axSpA with some metabolic syndrome features that are associated with an increased risk of CV disease.
PMID: 29303699 [PubMed]
Received: 02/05/2017 - Accepted : 01/08/2017 - In Press: 15/12/2017 - Published: 18/04/2018